$3 billion in venture capital in Australia in 2018 and growing
Expected returns from capital funding investments is increasing, particularly for Venture Capital (VC) and Angel Investor groups.
That's the takeaway from a report by William Buck Chartered Accountants and Advisors.
Mark Calvetti, Director of Corporate Advisory, says “Our experience shows that the expected rate of return from capital funding investments by Venture Capital groups in 2018 were between 30% to 50%. Whilst the expected rate of return by angel investors was even higher at 35-65%."
These returns are in line with the returns by these groups based on a survey carried out by Pepperdine Capital Markets in the US, which highlighted that the target rates of return by VC investors ranged between 25%-45%, with considerably higher expected rates for seed to early stage investments (30% to 45%); reaching as high as 38% to 60%.
Interestingly, bank loans had the lowest average rates of return (3-6%).
The chart below shows expected rate of return as per the Pepperdine Capital Markets report 2018:
The above chart shows a clear correlation between the size of loan or capital and the cost of borrowing – as the size of loan or capital increases, the cost of borrowing decreases.
According to Calvetti expectations depend on funding type – with earlier stage investments having a higher expected rate of return.
“What the evidence showed us is that there’s a wide range of investment returns depending on the type of investor and stage of investee business. Angel investors – seen at the earliest investment stage – are receiving the greatest returns, generally due to the greater perceived risk,” Calvetti says.
In 2018, the top Australian deals were dominated by software and biotechnology, coinciding with global trends, which were led by healthcare & biotechnology businesses (39% of target investments), followed by information technology (32%).
“Most VC investments are seen in the seed, start-up or early stage businesses, with each VC investor making an average of 2-5 investments in a year and, typically in the range of $1-$4 million – depending on the stage of the business being invested in.”
William Buck’s report also highlighted that the Capital Investment appetite is changing, both in Australia and across the globe; with a growing trend for mega-funds investing in late stage companies.
“There is a huge amount of VC activity across the globe. VC backed companies globally are projected to have raised approximately US$330 billion during the calendar year 2018. In comparison, that’s around 55.7% over the US$212 billion capital raised in 2017,” Calvetti says.
“There’s also a growing trend for mega-funds investing in late-stage companies, with late-stage rounds continuing to grow as a percentage of VC investments.
“Globally, the late stage rounds contributed 58% of the dollar value in 2018 compared to 49% in 2017. Interestingly, however, late stage rounds represented only seven percent of the total VC deals in 2018.”
In recent years, Australian private businesses are accessing more funding through Venture Capital.
“Historical data shows there’s a continued trend in Australia and globally of a declining number of deals, but an increase in average deal sizes, with globally the median deal size reaching US$40 million.
“Contrary to the small investment size appetite of a VC investor, Australia’s recent investments have been dominated by few large size VC investments in software and bio-tech.”
The VC investments in Australia reached A$3.1 billion across 161 deals over the 2018 calendar year, with an average deal size of A$20 million. This is more than double the value of VC investment in 2017 of A$1.4 billion across 183 deals, with an average deals size of A$7.5 million.
- Preqin defines Venture Capital deals in Australia to include all investments in Australia-based portfolio companies from both local and overseas investors. These investors can be GPs and LPs, sometimes unspecified investors as well.
- The dollar values in above chart has been calculated based on conversion of US dollar value to Australian dollar based on the average annual exchange rate for each calendar year, as sourced from Reserve Bank of Australia.
Calvetti says for software and biotech entities, VC has been a great way for private business to take the next step.
“There’s a real interest in tech driving VC demand. Software and biotech remain the key players for Venture Capital investments.”
Some of the top Australian transactions in 2018 included: Deputy – A Sydney based workforce management software company which recently raised US$81 million (A$111 million) in one of Australia’s largest Series B round; Clinical Genomics – A US based bio-technology company specialising in colorectal cancer (CRC) diagnosis raised A$33 million in series B round - essentially in convertible notes.
“Australia’s climate remains strong for biotech, with favourable R&D incentives. Also aiding Australia is their proximity to China, with Chinese companies representing eight of the top 10 deals globally, especially during the first half of calendar year 2018.”
Calvetti says for private business seeking funding, these findings are critical.
“When it comes to accessing funding, the type and source of capital depends upon various factors relevant to the individual requirements of each lender type – including stage of business, amount of funding required, expected rate of return, outlook of the business and other things such as the value-add of lender experience.”
The aim of William Buck’s report was to fill the gap for their clients who, when seeking funding didn’t know what rates of return an investor wanted.
“These findings give private business a guide to managing expectations and analysing various funding options when raising private capital funding.”
The report also discussed the preferred exit strategies for VC investors. Selling out the investment to another public company was at the top of the list, followed by selling to a private company and IPOs.
“Experience shows us that investors want a clear exit plan. Private business owners need to ensure succession planning is worked out at the beginning of their contract.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.